X0306 4 2014-10-28 false 0000911326 SYNAGEVA BIOPHARMA CORP GEVA 0001277495 BOESS CARSTEN 33 HAYDEN AVE LEXINGTON MA 02421 false true false false SVP, Chief Financial Officer Common Stock 2014-10-28 4 M false 1500 1.7 A 1500 D Common Stock 2014-10-28 4 M false 1000 23 A 2500 D Common Stock 2014-10-28 4 S false 1500 80 D 1000 D Common Stock 2014-10-28 4 S false 1000 80 D 0 D Common Stock 2014-10-30 4 M false 15050 1.7 A 15050 D Common Stock 2014-10-30 4 M false 7854 23 A 22904 D Common Stock 2014-10-30 4 S false 22904 80.11 D 0 D Stock Option (Right to Buy) 1.7 2014-10-28 4 M false 1500 0 D 2021-05-25 Common Stock 1500 38214 D Stock Option (Right to Buy) 23 2014-10-28 4 M false 1000 0 D 2021-12-20 Common Stock 1000 15146 D Stock Option (Right to Buy) 1.7 2014-10-30 4 M false 15050 0 D 2021-05-25 Common Stock 15050 23164 D Stock Option (Right to Buy) 23 2014-10-30 4 M false 7854 0 D 2021-12-20 Common Stock 7854 7292 D The stock option exercise and sale of shares of the Company's common stock reported in this Form 4 was effected pursuant to a Rule 10b5-1 plan adopted by the reporting person on September 24, 2014. The Stock Option granted the reporting person an option to purchase 158,840 shares of the Company's common stock (the "Shares"). 25% of the Shares vested and became exercisable on 05/16/2012, and 1/36 of the remainder of the Shares vest and become exercisable monthly thereafter. The Stock Option granted the reporting person an option to purchase 25,000 shares of the Company's common stock (the "Shares"). 25% of the Shares vested and became exercisable on 12/20/2012, and 1/36 of the remainder of the Shares vest and become exercisable monthly thereafter. This transaction was executed in multiple trades through a broker-dealer at prices ranging from $80 to $80.66. The price reported in this row reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price. /s/ Carsten Boess 2014-10-30